Bhalchandra Kawdikar’s Post

🚨 Big News in #ObesityMedicine! Structure Therapeutics just dosed the first patients in their trial for GSBR-1290, an oral GLP-1 receptor agonist that could change the game for obesity and type 2 diabetes treatment. 🌐 No needles, no refrigeration—just a once-daily pill that aims to deliver the same benefits as injectable meds like Ozempic and Mounjaro. Are oral GLP-1s the future of weight loss meds? 💊 We break down the details and what this means for the next generation of #GLP1 treatments on On The Pen. 👉 Read more at https://wix.to/2nDNYQV #OnThePen #GLP1 #ObesityMedicine

Living with carcinoid syndrome means managing daily challenges that impact quality of life, from persistent flushing and diarrhea to serious heart complications. The current standard of care is burdensome, involving depot injections of somatostatin peptide analogs that are associated with injection pain, inconsistent exposure, and breakthrough symptoms. At Crinetics, we are advancing research on an investigational, once-daily, nonpeptide, oral selective SST2 agonist, which is being studied for its potential to address the needs of patients with #CarcinoidSyndrome. Learn more: https://bit.ly/4cTcdzP  

"The BBB is vital for the brain, but its presence calls for novel and creative approaches for treating CNS diseases and CNS metastases. " "Drug delivery strategies (polymeric microparticles, nanoemulsions, liposomes etc.) are constantly advancing and evolving, presenting the possibility of delivering new therapeutic agents like TPDs across the BBB." from Prashant Agarwal et al. Prashant Agarwal, Darren Reid, and Mansoor Amiji. "CNS delivery of targeted protein degraders." Journal of Controlled Release 372 (2024): 661-673. #CNS #proteindegraders #drugdelivery #BBB #formulations Keywords: Targeted protein degraders Physicochemical properties CNS delivery Blood-brain barrier Formulations strategies

🚨 New FDA Approval: Duvyzat (givinostat) for Duchenne Muscular Dystrophy (DMD) #FDA #DRxVlogs Pragya Pandey Duvyzat is now approved for DMD patients aged 6 and older. Here's what this means: Non-steroidal Option: Duvyzat is the first non-steroidal drug approved for DMD, offering an alternative for patients who can't tolerate or don't respond to steroids. Targets Disease Progression: It works as a histone deacetylase (HDAC) inhibitor, reducing inflammation and muscle loss – key issues in DMD. Clinical Results: Studies showed Duvyzat slowed functional decline in DMD patients compared to placebo. Important Note: Duvyzat is not a cure. Potential side effects include diarrhea and low blood cell counts.

Aflibercept biosimilar MYL-1701P demonstrated comparable efficacy, safety, and immunogenicity profiles to reference aflibercept in a phase 3 clinical trial for treating diabetic macular edema. Findings suggest MYL-1701P can be a cost-effective alternative. https://ja.ma/4eB8qaB

Aflibercept biosimilar MYL-1701P demonstrated comparable efficacy, safety, and immunogenicity profiles to reference aflibercept in a phase 3 clinical trial for treating diabetic macular edema. Findings suggest MYL-1701P can be a cost-effective alternative. https://ja.ma/4d3IxiQ

Daily Dose 💉 of Internal Medicine: Drug-induced lupus erythematosus (DILE) DILE is a rare condition caused by certain medications. Here are some medications associated with DILE: 1. Hydralazine 2. Procainamide 3. Isoniazid 4. Minocycline 5. Quinidine 6. Chlorpromazine 7. Methyldopa 8. D-penicillamine 9. Tumor necrosis factor (TNF) inhibitors 10. Anti-TNF-alpha agents like infliximab, etanercept, adalimumab. It's important to note that not everyone who takes these medications will develop DILE, and the condition typically resolves after discontinuation of the offending drug. #medicine #healthcare

【Losartan Induced Angioedema, a Rare Case Report and the Dilemma of Using Angiotensin II Receptor Blockers in Patients with Previous Angioedema with Angiotensin Converting Enzyme Inhibitors】 Full article: https://lnkd.in/gVCZRsJC (Authored by Sayani Banerjee and Abdul Sajjad Pathan, from Weston General Hospital, University of Bristol & Weston, NHS Foundation Trust (UK), etc.) Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin II Receptor Blockers (ARBs) are groups of drugs that affect the renin-angiotensin-aldosterone system (RAAS). ACEIs induced angioedema is well known phenomenon and ARBs are often used as an alternative medication. This work reports a case of 78-year-old gentleman who presented to emergency department with losartan, an ARB induced #angioedema, who did not have history of any previous use of ACEIs, highlighting that ARB, however rarely, can cause angioedema. #Airway_Emergency

Did you know that S1P receptor modulators have been helping patients manage multiple sclerosis for nearly a decade? These oral medications target specific receptors to regulate immune responses and reduce inflammation, making them a promising treatment for conditions like ulcerative colitis. In our latest series, Dr. Laura Targownik dives into the benefits and risks of S1P receptor modulators. Click here to learn more: https://lnkd.in/e-u6yejB Pfizer #UlcerativeColitis

#BreakingNews: In one of the most highly anticipated #clinicaltrial readouts this year, an #RNAsilencing treatment developed by Alnylam Pharmaceuticals reduced the risk of death, heart-related hospital visits and hospitalizations by 28% compared to placebo in patients with a #heartmuscledisease. The results, announced Monday, pave the way for #Alnylam’s therapy #vutrisiran to become the first #RNAsilencingtherapy on the market for #ATTRamyloidosis with #cardiomyopathy, a condition in which misfolded proteins build up in the heart and can result in heart failure. If approved, Alnylam could enter a multibillion-dollar market currently dominated by Pfizer. Vutrisiran is already approved as Amvuttra for ATTR amyloidosis with polyneuropathy, where the misfolded proteins affect the nerves. Alnylam believes that it can potentially reach 10 times more patients in the expanded indication, as the heart manifestation of the disease has been estimated to impact as many as 500,000 globally. “We believe with the data we have in hand, this will become the new standard of care in patients with ATTR cardiomyopathy,” Alnylam CEO Dr. Yvonne Greenstreet told Endpoints News on Saturday. “This is really, really tremendous data and clearly a huge opportunity for Alnylam.” Read more from Endpoints News 👇🏼